The US Food and Drug Administration (FDA) has accepted filing of a supplemental biologics licence application (sBLA) by Seattle Genetics for its ADCETRIS (brentuximab vedotin) in combination with chemotherapy as frontline treatment of advanced classical Hodgkin lymphoma.

The agency has granted priority review for the filing, and the Prescription Drug User Fee Act (PDUFA) target action date is 1 May.

Currently being assessed in 70 clinical trials, ADCETRIS is a monoclonal antibody-drug conjugate (ADC) designed to target CD30, which is considered as a defining marker of the disease.

The sBLA submission is based on positive data obtained during the Phase III ECHELON-1 trial that aimed to establish the ability of ADCETRIS and chemotherapy combination to extend modified progression-free survival in 1,334 previously untreated patients with advanced classical Hodgkin lymphoma.

“The agency has granted priority review for the filing, and the Prescription Drug User Fee Act (PDUFA) target action date is 1 May.”

ECHELON-1 is reported to have met the primary endpoint, along with favourable secondary endpoints and consistent safety profile compared to the single-agent components of the combination.

Seattle Genetics president and CEO Clay Siegall said: “We recently reported the primary data from the phase 3 ECHELON-1 clinical trial in the Plenary Scientific Session of the 2017 ASH Annual Meeting with simultaneous publication in the New England Journal of Medicine.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The data demonstrated superior activity of the ADCETRIS-containing regimen over standard of care, and we are working with the FDA to make this bleomycin-free regimen available to newly diagnosed advanced Hodgkin lymphoma patients as soon as possible.”

The firm is co-developing ADCETRIS with Takeda and has commercialisation rights in the US and Canada, while the latter holds rights in all the remaining countries.